---
title: "North China Pharmaceutical Company.Ltd (600812.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600812.SH.md"
symbol: "600812.SH"
name: "North China Pharmaceutical Company.Ltd"
industry: "Pharmaceuticals"
datetime: "2026-05-21T16:08:41.559Z"
locales:
  - [en](https://longbridge.com/en/quote/600812.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600812.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600812.SH.md)
---

# North China Pharmaceutical Company.Ltd (600812.SH)

## Company Overview

North China Pharmaceutical Company.Ltd engages in the research and development, production, and sales of pharmaceutical products in China and internationally. The company primarily offers anti-infective drugs, biotechnology drugs, cardiovascular cerebrovascular, immunomodulators, and vitamins and health products. It also provides chemical pharmaceuticals; and biological, agricultural, and veterinary drugs. North China Pharmaceutical Company.Ltd was founded in 1992 and is headquartered in Shijiazhuang, China.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.ncpc.com](https://www.ncpc.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: C (0.60)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 109 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -10.78% |  |
| Net Profit YoY | -3.18% |  |
| P/B Ratio | 1.49 |  |
| Dividend Ratio | 0.62% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8253922483.80 |  |
| Revenue | 8803610123.74 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 2.93% | C |
| Profit Margin | 1.83% | C |
| Gross Margin | 28.95% | C |
| Revenue YoY | -10.78% | E |
| Net Profit YoY | -3.18% | C |
| Total Assets YoY | -2.46% | D |
| Net Assets YoY | 2.70% | C |
| Cash Flow Margin | 727.71% | A |
| OCF YoY | -10.78% | E |
| Turnover | 0.41 | C |
| Gearing Ratio | 67.68% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - North China Pharmaceutical Company.Ltd",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-10.78%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-3.18%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.49",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.62%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8253922483.80",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "8803610123.74",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "2.93%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "1.83%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "28.95%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-10.78%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-3.18%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-2.46%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "2.70%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "727.71%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-10.78%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.41",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "67.68%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 50.82 | 103/215 | 63.13 | 55.93 | 52.40 |
| PB | 1.47 | 44/215 | 1.95 | 1.83 | 1.73 |
| PS (TTM) | 0.93 | 7/215 | 1.08 | 1.02 | 0.98 |
| Dividend Yield | 0.63% | 120/215 | 0.54% | 0.51% | 0.44% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2025-02-06T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 6.42 |
| Highest Target | 7.30 |
| Lowest Target | 7.30 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600812.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600812.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600812.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600812.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**